Jared Holz, Mizuho Securities America healthcare sector strategist, joins 'Squawk Box' to break down the quarterly earnings ...

Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...